SCHEMBL354126

SCHEMBL354126

CCCCCC=CCC=CCC=CCC=CCCC(O)C(=O)OC(=O)C(O)CCCCCCCCCCCCCCCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
F7 P08709 3/20 0.50
F3 P13726 3/20 0.50
PPARG P37231 2/20 0.50
PPARD Q03181 2/20 0.50
PPARA Q07869 2/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
DUSP3 P51452 1/20 0.50
PTPN7 P35236 1/20 0.50
FFAR1 O14842 1/20 0.50
LMNA P02545 1/20 0.50
FABP3 P05413 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP19A1 P11511 1/20 0.50
FABP4 P15090 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17352282 0.92 FAAH (0.53) ALDH1A1DUSP3HPGDFAAH
SCHEMBL17352278 0.87 DGKA (0.52) FFAR1FFAR4FAAH
SCHEMBL27786702 0.87 ALDH1A1 (0.51) ALDH1A1KDM4EF7F3PPARG
SCHEMBL17512200 0.87 ALDH1A1 (0.51) ALDH1A1KDM4EF7F3PPARG
SCHEMBL31324769 0.85 NFKB1 (0.52) NFKB1NFKB2RELAFAAH
SCHEMBL31324709 0.85 NFKB1 (0.52) ALDH1A1KDM4EF7F3PPARG
SCHEMBL31324729 0.84 MGLL (0.51) ALDH1A1KDM4EPPARGPPARDPPARA
SCHEMBL28765162 0.83 MGLL (0.55) ALDH1A1KDM4EF7F3PPARG
SCHEMBL354125 0.82 NFKB1 (0.48) ALDH1A1KDM4EF7F3PPARG
SCHEMBL28070069 0.82 DGKA (0.58) DUSP3FFAR1LMNAFABP4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120093737-A1 LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC. 2012-04-19 US disclosed
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING SEDERMA (FR) 2012-03-29 US disclosed
EP-2419076-A2 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES Sederma (FR) 2012-02-22 EP disclosed
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES SEDERMA (FR) 2012-02-02 US disclosed
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES SEDERMA (FR) 2012-01-19 US disclosed
EP-2382231-A2 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES Sederma (FR) 2011-11-02 EP disclosed
EP-2382230-A2 KXK-PEPTIDE COMPOSITIONS FOR COSMETIC AND DERMO-PHARMACEUTIC USES Sederma (FR) 2011-11-02 EP disclosed
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans SEDERMA, S.A.S. (FR) 2011-10-13 US disclosed
EP-2367852-A1 COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS Sederma (FR) 2011-09-28 EP disclosed
EP-2046283-B1 COMPOSITION COMPRISING SARSASAPOGENIN SEDERMA SA (FR) 2011-03-16 EP disclosed
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle SEDERMA (FR) 2011-02-24 US disclosed
US-20110033507-A1 Polypeptides KXK and Their Use SEDERMA (FR) 2011-02-10 US disclosed
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL SEDERMA, S.A.S. (FR) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES CUTA, PLOD3, MC1R ALDH1A1 2211/4885KDM4E 4490/4885F7 1833/4885
US-20110033507-A1 Polypeptides KXK and Their Use NPR3, NGLY1, NPR1 ALDH1A1 4431/4885KDM4E 1679/4885F7 1413/4885
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING ARGLU1, CUTA, ARG1 ALDH1A1 4229/4885KDM4E 1711/4885F7 3094/4885
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle TYR, XPA, MC1R ALDH1A1 2097/4885KDM4E 2698/4885F7 1212/4885
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL AQP1, CUTA, AQP3 ALDH1A1 3403/4885KDM4E 3523/4885F7 1520/4885
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans GLA, OGA, CUTA ALDH1A1 848/4885KDM4E 1622/4885F7 388/4885
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES DPM1, MC1R, SLTM ALDH1A1 521/4885KDM4E 4293/4885F7 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.